ABAXIS, Inc. (NASDAQ:ABAX) Set to Announce Quarterly Earnings on Thursday
ABAXIS, Inc. (NASDAQ:ABAX) is scheduled to issue its quarterly earnings data after the market closes on Thursday, July 27th. Analysts expect the company to announce earnings of $0.33 per share for the quarter.
ABAXIS (NASDAQ:ABAX) last issued its quarterly earnings data on Thursday, April 27th. The medical research company reported $0.33 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.33. ABAXIS had a return on equity of 11.37% and a net margin of 14.40%. The company had revenue of $58.20 million for the quarter, compared to analysts’ expectations of $58.04 million. During the same period in the previous year, the firm posted $0.36 earnings per share. The firm’s revenue for the quarter was up 2.2% on a year-over-year basis. On average, analysts expect ABAXIS to post $1.22 EPS for the current fiscal year and $1.44 EPS for the next fiscal year.
Shares of ABAXIS, Inc. (NASDAQ:ABAX) opened at 50.83 on Thursday. The firm’s 50-day moving average price is $51.72 and its 200 day moving average price is $49.65. ABAXIS, Inc. has a 52 week low of $44.12 and a 52 week high of $55.95. The company has a market capitalization of $1.15 billion, a PE ratio of 35.37 and a beta of 0.84.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/20/abaxis-inc-nasdaqabax-set-to-announce-quarterly-earnings-on-thursday.html.
In other ABAXIS news, insider Achim Henkel sold 650 shares of the firm’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $48.87, for a total value of $31,765.50. Following the transaction, the insider now directly owns 58,950 shares of the company’s stock, valued at approximately $2,880,886.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.10% of the company’s stock.
ABAX has been the topic of a number of research reports. Zacks Investment Research lowered shares of ABAXIS from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. Stifel Nicolaus reissued a “hold” rating and issued a $48.00 target price on shares of ABAXIS in a research note on Friday, July 14th. Finally, Aegis initiated coverage on shares of ABAXIS in a research note on Friday, June 9th. They issued a “hold” rating and a $56.50 target price on the stock. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $47.88.
Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.
Receive News & Ratings for ABAXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABAXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.